Sana Biotechnology, Inc.
For the period ended Sep 30, 2026. Filed Nov 5, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 5, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
15. Net income (loss) per share
Basic net income (loss) per common share is calculated by dividing net income (loss) attributable to common stockholders by the weighted-average number of common shares outstanding during the relevant period, without consideration of potentially dilutive securities. Diluted net income (loss) per common share is calculated by dividing net income (loss) attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the relevant period, adjusted for the effect of potentially dilutive securities. The dilutive effect of RSUs and stock options are calculated using the treasury stock method.
The following table summarizes the calculation of basic and diluted net income (loss) per share of common stock:
| Three Months Ended September 30, | Nine Months Ended September 30, | |||
|---|---|---|---|---|
| 2026 | 2025 | 2026 | 2025 | |
| (in thousands, except per share amounts) | ||||
| Basic net income (loss) per common share: | ||||
| Net income (loss) attributable to common stockholders | $20,401 | $(42,152) | $(90,444) | $(185,341) |
| Weighted-average number of common shares – basic | 307,002 | 260,494 | 293,286 | 245,580 |
| Basic net income (loss) per common share | $0.07 | $(0.16) | $(0.31) | $(0.75) |
| Diluted net income (loss) per common share: | ||||
| Net income (loss) attributable to common stockholders | $20,401 | $(42,152) | $(90,444) | $(185,341) |
| Weighted-average number of common shares – basic | 307,002 | 260,494 | 293,286 | 245,580 |
| Effect of dilutive securities: | ||||
| Stock options and restricted stock units | 1,788 | - | - | - |
| Weighted-average number of common shares – diluted | 308,790 | 260,494 | 293,286 | 245,580 |
| Diluted net income (loss) per common share | $0.07 | $(0.16) | $(0.31) | $(0.75) |
The following securities were excluded from the computation of net income (loss) per diluted share of common stock for periods presented as their effect would have been anti-dilutive:
| Three Months Ended September 30, | Nine Months Ended September 30, | |||
|---|---|---|---|---|
| 2026 | 2025 | 2026 | 2025 | |
| (in thousands) · (in thousands) | ||||
| Options to purchase common stock | 25,744 | 23,364 | 28,054 | 23,364 |
| Unvested RSUs | 1,246 | 3,489 | 4,588 | 3,489 |
| Total | 26,990 | 26,853 | 32,642 | 26,853 |
- Employee benefit plan
In January 2019, the Company adopted a 401(k) retirement and savings plan (the 401(k) Plan) covering all employees. The 401(k) Plan allows employees to make pre- and post-tax contributions up to the maximum allowable amount set by the IRS. The Company matches each participant’s 401(k) contributions in cash, up to $4,500 per year per participant, effective as of January 1, 2026.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.